Neurocrine Biosciences | NBIX - Trade Creditors

Stock Price
140.56
Daily Change
2.70 1.96%
Monthly
2.34%
Yearly
-6.61%
Q1 Forecast
131.87

Neurocrine Biosciences reported $119.9M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
AbbVie USD 32.25B 1.2B Jun/2025
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 19.55M 2.02M Sep/2025
ALKERMES USD 68M 31.21M Sep/2025
Alnylam Pharmaceuticals USD 117.59M 15.2M Sep/2025
Amgen USD 19.64B 1.61B Sep/2025
Biogen USD 413.1M 4.7M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Cytokinetics USD 22.08M 46.46M Sep/2025
Dynavax Technologies USD 3.95M 1.25M Sep/2025
Exelixis USD 25.35M 471K Sep/2025
Gilead Sciences USD 808M 226M Sep/2025
Halozyme Therapeutics USD 15.36M 3.33M Sep/2025
Incyte USD 171.92M 1.24B Sep/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
Neurocrine Biosciences USD 119.9M 15.3M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Prothena USD 10.5M 1.7M Sep/2025
Regeneron Pharmaceuticals USD 5.83B 4.93B Dec/2025
Repligen USD 29.43M 3.8M Sep/2025
Sarepta Therapeutics USD 94.02M 42.69M Sep/2025
Teva Pharmaceutical Industries USD 2.53B 176M Dec/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Vertex Pharmaceuticals USD 4.03B 320.8M Sep/2025